Balancing access to opioid substitution treatment (OST) with preventing the diversion of opioid substitution medications in Europe: challenges and implications 10. February 2021, section EUDA news
10. March 2026 From essential medicine to illicit commodity: new EU report reveals how ketamine diversion is fuelling the illicit market in Europe Ketamine produced legitimately outside the EU to make medicines is increasingly finding its way onto Europe’s illicit drug...
